Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novartis Pauses Autoimmune Cell Therapy Studies After Deaths" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Новости GxP, European Biotechnology Magazine and Pharmaceutical Executive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 73d ago.
Quick answers
Why is "Novartis Pauses Autoimmune Cell Therapy Studies After Deaths" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (3)
- Novartis pauses eight CAR-T trials after three patient deaths Новости GxP · 75d ago
- Novartis: Three deaths put CAR-T expansion into autoimmune diseases on hold European Biotechnology Magazine · 75d ago
- Novartis and BMS Halt CAR-T Trials Pharmaceutical Executive · 75d ago
Topics
Related trends
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
Novartis has agreed to a massive new mRNA drug deal with Chinese startup Abogen worth up to $7.8 billion.
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
Kyverna advances its cell therapy toward an FDA submission as new one-year durability data emerges.
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Roche's experimental drug sefaxersen meets its primary endpoint in a late-stage study for the autoimmune disease IgAN.